Zonisamide
Approved · EMAAlso known as Zonegran, Zonisade, Zonisamida, 1,2-Benzisoxazole-3-methanesulfonamide+2 more
Zonegran, Zonisade, Zonisamida, 1,2-Benzisoxazole-3-methanesulfonamide, 3-(Sulfamoylmethyl)-1,2-benzisoxazole, Zonisamidum.
Recent clinical, regulatory, research and industry developments relating to this drug.
Safety and Efficacy of Zonisamide Versus Topiramate in Migraine
Zonisamide Versus Propranolol in Migraine, a Randomized Controlled Single-blinded Trial
Pharmaceutical Interventions for Noise-Induced Hearing Loss-Acute Exposure Treatment
Modification of Epilepsy Screen Questionnaire and Treatment Feasibility Evaluation
Interdisciplinary Study of Two Novel Anticonvulsants in Alcoholism
Role of Zonisamide in Advanced Parkinson's Disease (PD) in Egyptian Population: Pilot Study
Approval: Zonisamide Viatris (previously Zonisamide Mylan) (EMA)
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Regulatory timeline
The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.
Indication: Monotherapy in the treatment of partial seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy; adjunctive therapy in the treatment of partial… Show full indicationShow less
Monotherapy in the treatment of partial seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy; adjunctive therapy in the treatment of partial seizures, with or without secondary generalisation, in adults, adolescents, and children aged 6 years and above.
Indication: Zonegran is indicated as: monotherapy in the treatment of partial seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy; adjunctive therapy… Show full indicationShow less
Zonegran is indicated as: monotherapy in the treatment of partial seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy; adjunctive therapy in the treatment of partial seizures, with or without secondary generalisation, in adults, adolescents, and children aged six years and above.
Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
Recent completions
Trials that read out recently, adding to the completed evidence base.
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- ClinicalTrials.gov — clinical trials
- Regulatory event sources are credited in the Regulatory Timeline above.